We serve Chemical Name:methyl 1-cyanobicyclo[2.2.2]octane-4-carboxylate CAS:54202-05-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![methyl 1-cyanobicyclo[2.2.2]octane-4-carboxylate](https://a.dearchem.com/CAS2/54202-05-0.png)
Chemical Name:methyl 1-cyanobicyclo[2.2.2]octane-4-carboxylate
CAS.NO:54202-05-0
Synonyms:methyl 1-cyanobicyclo[2.2.2]octane-4-carboxylate
Molecular Formula:C11H15NO2
Molecular Weight:193.24200
HS Code:2926909090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:50.09000
Exact Mass:193.11000
LogP:2.02358
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like methyl 1-cyanobicyclo[2.2.2]octane-4-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 1-cyanobicyclo[2.2.2]octane-4-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 1-cyanobicyclo[2.2.2]octane-4-carboxylate Use and application,methyl 1-cyanobicyclo[2.2.2]octane-4-carboxylate technical grade,usp/ep/jp grade.
Related News: He joins us at a pivotal time as our Jinkō® platform goes from strength to strength as we expand our portfolio of partnerships. Grégoire’s strategic and operational expertise will be a vital part of our future success in accelerating and de-risking clinical trials. 8,9,10-trifluoro-6H-pyrido[1,2-a]quinazolin-6-one manufacturers Patients having Zynteglo treatment for beta thalassaemia also need conditioning treatment to clear out their bone marrow cells before receiving Zynteglo. Healthcare professionals should therefore explicitly inform patients receiving Zynteglo of the increased risk of blood cancers from medicines used in conditioning treatments. 2-(4-([1,1′-biphenyl]-4-carboxamido)butyl)-1,2,3,4-tetrahydroisoquinolin-7-yl pyridine-3-sulfonate suppliers Mene Pangalos, executive vice president, BioPharmaceuticals R&D, said: “The data being presented at EULAR add to the growing body of evidence for anifrolumab that demonstrate a compelling clinical profile with the potential to address significant unmet medical needs in this debilitating disease. (2S-(2α,3αβ,7αβ))-1-(2-((1-carboxy-3-phenylpropyl)thio)-1-oxopropyl)octahydro-1H-indole-2-carboxylic acid vendor & factory.
